Metabolic reprogramming in non-small cell lung cancer: unraveling therapeutic vulnerabilities and resistance mechanisms

Tamer A. Addissouky

doi:10.1007/s44162-026-00147-9

January 17, 2026Journal of Rare DiseasesOpen Access

Metabolic reprogramming in non-small cell lung cancer: unraveling therapeutic vulnerabilities and resistance mechanisms

View Full Paper

Ask AI

Bookmark

Share

Key Points

Resistance mechanisms significantly impact treatment effectiveness in non-small cell lung cancer, affecting patient outcomes.
The study identifies key biomarkers associated with metabolic reprogramming in non-small cell lung cancer cases, highlighting therapeutic targets.
Observational analysis of various treatment interventions highlights the need for innovative approaches to target metabolic vulnerabilities effectively.
The findings point to the potential for developing tailored therapies based on metabolic profiles, indicating that more research is essential.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational analysis reveals therapeutic vulnerabilities and resistance mechanisms in non-small cell lung cancer, suggesting new treatment insights.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tamer A. Addissouky (2026) studied this question.

synapsesocial.com/papers/69a759f9c6e9836116a1f697 https://doi.org/10.1007/s44162-026-00147-9

View Full Paper

Ask AI

Bookmark

Share

Metabolic reprogramming in non-small cell lung cancer: unraveling therapeutic vulnerabilities and resistance mechanisms

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Metabolic reprogramming in non-small cell lung cancer: unraveling therapeutic vulnerabilities and resistance mechanisms

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading